Latest Ambrisentan Stories
WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc.
Monthly liver enzyme testing is no longer required SILVER SPRING, Md., March 4, 2011 /PRNewswire-USNewswire/ -- The U.S.
WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while United Therapeutics' Tyvaso and Adcirca--launched in 2009--are each prescribed by more than half of surveyed pulmonologists in the specialized pulmonary arterial hypertension (PAH) center setting, Adcirca is much more widely used than Tyvaso among surveyed non-PAH-center physicians. The new Physician & Payer Forum...
Research team reviews outcomes after 2 years of treatment with ambrisentan.
Can these drugs help with a wider array of diseases? Expert to address conference of experts Being sponsored by the American Physiological Society (APS).
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results of a two-year (104-week), open-label, uncontrolled, extension study (ARIES-E) of Letairis(R) in patients with pulmonary arterial hypertension (PAH) (WHO Group 1).
Actelion has announced that Tracleer, a dual endothelin receptor antagonist, has been approved in the European Union for the treatment of patients with mildly symptomatic pulmonary arterial hypertension.
WASHINGTON (Reuters) - Encysive Pharmaceuticals Inc.'s drug Thelin is "approvable" for treating a rare, often-fatal lung condition, a U.S. Food and Drug Administration (FDA) spokeswoman said on Friday.
- A serpent whose bite was fabled to produce intense thirst.